Cactus Life Sciences Top 5 Trends of 2024

Cactus Life Sciences’ Top 5 Trends of 2024: Insights Driving Tomorrow’s MedComms

Here, we revisit our most thought-provoking articles and whitepapers, each addressing pivotal trends that influence the ever-evolving biopharma landscape...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical

This whitepaper explores the role of social media in...
Digital Publication Extenders, Digital Icons, Digital Publications

Digital Publication Extenders: Creating an Ecosystem for a More Engaging and Informative Experience

While creating digital publication extenders may seem complex, Cactus Life Sciences can assist in developing...
Medical Review

Uncovering the Benefits of Medical Review: A Comprehensive Overview

Medical review promises scientific data accuracy and has paramount importance at all the stages of...
Periodic Safety Update Report (PSUR) - Medical Device

Periodic Safety Update Report (PSUR): A Breakdown of MDCG 2022-21

A well-structured, clear, and concise PSUR enables a seamless notified body review. Read our key...
Medical Device Regulation

Clinical Evidence: How Much Is Enough?

Ensuring the safety and functionality of your medical device is vital. But how much clinical...
Health Literacy

Health Literacy – Cactus Life Sciences Leads the Way

It’s our responsibility as an industry to emphasize the importance of health literacy and help...
Patient Inclusivity Survey - PM360 and Cactus Life Sciences

Patient Inclusivity Survey

How many life sciences companies are actually making an effort to include patients in things...

Learn more ABOUT our company.